TriangleNCT03770260 · OUTCOME
Overall Response Rate (Dose Expansion)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Up to 2 Years after Treatment
What was measured
To determine the overall responses in patients receiving pevonedistat and ixazomib
Analysis population: The dose escalation phase was not completed in order to enroll to the dose expansion phase
Groups in this outcome
Dose Expansion
Patients receive pevonedistat the maximum tolerated dose (MTD) as determined in the dose escalation phase by infusion ande ixazomib citrate 4 mg by mouth on days 1, 8, and 15 of each 28-day cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Dose Expansion | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- To determine the overall responses in patients receiving pevonedistat and ixazomib
- groups
- description
- Patients receive pevonedistat the maximum tolerated dose (MTD) as determined in the dose escalation phase by infusion ande ixazomib citrate 4 mg by mouth on days 1, 8, and 15 of each 28-day cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Dose Expansion
- population Description
- The dose escalation phase was not completed in order to enroll to the dose expansion phase
- reporting Status
- POSTED
- time Frame
- Up to 2 Years after Treatment
- title
- Overall Response Rate (Dose Expansion)
- type
- PRIMARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice